Natural killer cell monitoring in cutaneous melanoma - new dynamic biomarker.
B-lymphocytes
NK cells
T-lymphocytes
melanoma
tumor-bearing mice
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
21
09
2018
accepted:
20
12
2018
entrez:
5
4
2019
pubmed:
5
4
2019
medline:
5
4
2019
Statut:
ppublish
Résumé
Melanoma is responsible for most skin cancer deaths in humans. The immune system plays a major role in regulating tumor cell proliferation by initiating defence responses against tumor aggression. Research on murine cancer models allow for a better understanding of immune response in malignancies, revealing specific changes of the immune status in the presence of tumors. Melanoma resistance to conventional therapies and its high immunogenicity justify the development of new therapies. These features reinforce melanoma as a suitable model for studying antitumor immunity. Recent findings on NK cell activation in cancer patients indicate that several important parameters, such as tumor capacity to modulate the function and phenotype of NK cells, require consideration for the choice of an NK-based therapy. In this study, we investigated T-CD4
Identifiants
pubmed: 30944615
doi: 10.3892/ol.2019.10069
pii: OL-0-0-10069
pmc: PMC6444282
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4197-4206Références
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6336-40
pubmed: 10339588
Lancet. 2000 Nov 25;356(9244):1795-9
pubmed: 11117911
Blood. 2003 Apr 15;101(8):3052-7
pubmed: 12480696
Nat Rev Immunol. 2003 May;3(5):413-25
pubmed: 12766763
J Immunol Methods. 2004 Nov;294(1-2):15-22
pubmed: 15604012
J Immunol. 2006 Feb 1;176(3):1517-24
pubmed: 16424180
Blood. 2006 Jul 1;108(1):246-52
pubmed: 16556890
Genes Dev. 2006 Aug 15;20(16):2149-82
pubmed: 16912270
J Immunol. 2007 Jan 1;178(1):85-94
pubmed: 17182543
J Immunol. 2007 Apr 15;178(8):4764-70
pubmed: 17404256
J Exp Med. 2007 Oct 29;204(11):2561-8
pubmed: 17923504
J Leukoc Biol. 2008 Oct;84(4):1039-46
pubmed: 18664530
Blood. 2009 May 28;113(22):5488-96
pubmed: 19234143
Expert Rev Mol Diagn. 2010 Oct;10(7):897-919
pubmed: 20964610
Clin Dev Immunol. 2011;2011:316314
pubmed: 21403861
Expert Rev Mol Diagn. 2011 Jun;11(5):461-4
pubmed: 21707453
Tissue Antigens. 2011 Aug;78(2):81-8
pubmed: 21726202
Br J Dermatol. 2011 Nov;165(5):953-65
pubmed: 21729024
J Immunol Methods. 2011 Sep 30;372(1-2):187-95
pubmed: 21839083
Nat Rev Immunol. 2011 Aug 26;11(10):645-57
pubmed: 21869816
Adv Clin Chem. 2012;58:89-140
pubmed: 22950344
J Immunol. 2013 Jan 15;190(2):712-22
pubmed: 23241894
J Immunol. 2013 Jun 15;190(12):6269-76
pubmed: 23656738
Lab Anim (NY). 2013 Jun;42(6):217-24
pubmed: 23689461
PLoS One. 2013 Jun 11;8(6):e65599
pubmed: 23776508
Am J Clin Pathol. 2013 Dec;140(6):853-66
pubmed: 24225754
J Immunoassay Immunochem. 2015;36(6):559-66
pubmed: 25839711
Front Immunol. 2015 Sep 25;6:495
pubmed: 26441997
Oncol Rep. 2016 May;35(5):2516-28
pubmed: 26986013
J Immunol. 2016 Apr 1;196(7):2923-31
pubmed: 26994304
Oncol Lett. 2016 May;11(5):3354-3360
pubmed: 27123116
Oncol Rep. 2017 Sep;38(3):1327-1340
pubmed: 28713981
Acta Dermatovenerol Croat. 2018 Apr;26(1):64-67
pubmed: 29782304